Patents by Inventor Keiko Katsumi

Keiko Katsumi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240352142
    Abstract: It is an object of the present invention to provide an ROS production-enhancing agent. According to the present invention, an ROS production-enhancing agent, comprising a substance that recognizes a transferrin receptor, is provided.
    Type: Application
    Filed: August 26, 2022
    Publication date: October 24, 2024
    Applicant: PERSEUS PROTEOMICS INC.
    Inventors: Keiko KATSUMI, Junpei OYA, Keisuke ISHII, Aya SAKAMOTO
  • Publication number: 20240288453
    Abstract: It is an object of the present invention to provide a method for determining the medicinal effect or sensitivity of an anti-transferrin receptor antibody. According to the present invention, provided is a method for determining the medicinal effect or sensitivity of an anti-human transferrin receptor antibody having an action to inhibit the binding between human transferrin and a human transferrin receptor, wherein the method uses an intracellular iron content as an indicator.
    Type: Application
    Filed: October 8, 2021
    Publication date: August 29, 2024
    Applicants: National University Corporation Tokai National Higher Education and Research System, PERSEUS PROTEOMICS INC.
    Inventors: Hitoshi KIYOI, Yuichi ISHIKAWA, Marie NAKASHIMA, Yuta OHIRA, Junpei OYA, Fumiko NOMURA, Keiko KATSUMI, Aya SAKAMOTO, Yoshinori UKAI, Tadashi MATSUURA
  • Publication number: 20220332838
    Abstract: It is an object of the present invention to provide an agent for inhibiting iron uptake into cells wherein the agent targets TfR, and an agent for inhibiting the binding between human Tf and human TfR. The present invention provides an agent for inhibiting iron uptake into cells which comprises an antibody which recognizes the amino acids at positions 629 to 633 of a human transferrin receptor.
    Type: Application
    Filed: November 19, 2019
    Publication date: October 20, 2022
    Applicant: PERSEUS PROTEOMICS INC.
    Inventors: Lilin ZHANG, Fumiko NOMURA, Keiko KATSUMI, Romi KOTAKA, Yuta OHIRA
  • Patent number: 9328160
    Abstract: It is an object of the present invention to provide an anti-cadherin antibody having a high internalization capacity and provide an anti-cadherin antibody-drug conjugate that effectively kills cadherin-expressing cancer cells with the use of such antibody. The present invention provides an anti-cadherin antibody which recognizes a cadherin domain 1 (EC1) of cadherin and exhibits a high internalization capacity.
    Type: Grant
    Filed: October 28, 2011
    Date of Patent: May 3, 2016
    Assignee: PERSEUS PROTEOMICS INC.
    Inventors: Keisuke Ishii, Keiko Katsumi, Tadashi Matsuura, Yukio Sudo, Katsuyuki Mitomo, Katsushi Kouda
  • Patent number: 9017683
    Abstract: It is an object of the present invention to provide an anti-cadherin antibody having high antibody-dependent cellular cytotoxicity. The present invention provides an anti-cadherin antibody, which recognizes any one of an upstream region of EC1, a cadherin domain 4 (EC4) and a cadherin domain 5 (EC5), wherein an antibody-dependent cellular cytotoxicity at an antibody concentration of 1 ?g/mL is 30% or more.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: April 28, 2015
    Assignees: The University of Tokyo, Perseus Proteomics Inc.
    Inventors: Hiroyuki Aburatani, Lilin Zhang, Keisuke Ishii, Katsushi Kouda, Aya Sakamoto, Keiko Katsumi, Hiroshi Onishi, Yoko Kayukawa
  • Publication number: 20130317201
    Abstract: It is an object of the present invention to provide an anti-cadherin antibody having a high internalization capacity and provide an anti-cadherin antibody-drug conjugate that effectively kills cadherin-expressing cancer cells with the use of such antibody. The present invention provides an anti-cadherin antibody which recognizes a cadherin domain 1 (EC1) of cadherin and exhibits a high internalization capacity.
    Type: Application
    Filed: October 28, 2011
    Publication date: November 28, 2013
    Applicant: PERSEUS PROTEOMICS INC.
    Inventors: Keisuke Ishii, Keiko Katsumi, Tadashi Matsuura, Yukio Sudo, Katsuyuki Mitomo, Katsushi Kouda
  • Publication number: 20130243771
    Abstract: It is an object of the present invention to provide an anti-cadherin antibody having high antibody-dependent cellular cytotoxicity. The present invention provides an anti-cadherin antibody, which recognizes any one of an upstream region of EC1, a cadherin domain 4 (EC4) and a cadherin domain 5 (EC5), wherein an antibody-dependent cellular cytotoxicity at an antibody concentration of 1 ?g/mL is 30% or more.
    Type: Application
    Filed: May 3, 2013
    Publication date: September 19, 2013
    Applicants: PERSEUS PROTEOMICS INC., THE UNIVERSITY OF TOKYO
    Inventors: Hiroyuki ABURATANI, Lilin ZHANG, Keisuke ISHII, Katsushi KOUDA, Aya SAKAMOTO, Keiko KATSUMI, Hiroshi ONISHI, Yoko KAYUKAWA
  • Publication number: 20130245232
    Abstract: It is an object of the present invention to provide an anti-cadherin antibody having high antibody-dependent cellular cytotoxicity. The present invention provides an anti-cadherin antibody, which recognizes any one of an upstream region of EC1, a cadherin domain 4 (EC4) and a cadherin domain 5 (EC5), wherein an antibody-dependent cellular cytotoxicity at an antibody concentration of 1 ?g/mL is 30% or more.
    Type: Application
    Filed: May 3, 2013
    Publication date: September 19, 2013
    Applicants: PERSEUS PROTEOMICS INC., THE UNIVERSITY OF TOKYO
    Inventors: Hiroyuki ABURATANI, Lilin ZHANG, Keisuke ISHII, Katsushi KOUDA, Aya SAKAMOTO, Keiko KATSUMI, Hiroshi ONISHI, Yoko KAYUKAWA
  • Patent number: 8455249
    Abstract: It is an object of the present invention to provide an anti-cadherin antibody having high antibody-dependent cellular cytotoxicity. The present invention provides an anti-cadherin antibody, which recognizes any one of an upstream region of EC1, a cadherin domain 4 (EC4) and a cadherin domain 5 (EC5), wherein an antibody-dependent cellular cytotoxicity at an antibody concentration of 1 ?g/mL is 30% or more.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: June 4, 2013
    Assignees: The University of Tokyo, Perseus Proteomics Inc.
    Inventors: Hiroyuki Aburatani, Lilin Zhang, Keisuke Ishii, Katsushi Kouda, Aya Sakamoto, Keiko Katsumi, Hiroshi Onishi, Yoko Kayukawa
  • Publication number: 20120136140
    Abstract: It is an object of the present invention to provide an anti-cadherin antibody having high antibody-dependent cellular cytotoxicity. The present invention provides an anti-cadherin antibody, which recognizes any one of an upstream region of EC1, a cadherin domain 4 (EC4) and a cadherin domain 5 (EC5), wherein an antibody-dependent cellular cytotoxicity at an antibody concentration of 1 ?g/mL is 30% or more.
    Type: Application
    Filed: April 30, 2010
    Publication date: May 31, 2012
    Applicants: PERSEUS PROTEOMICS INC., THE UNIVERSITY OF TOKYO
    Inventors: Hiroyuki Aburatani, Lilin Zhang, Keisuke Ishi, Katsushi Kouda, Aya Sakamoto, Keiko Katsumi, Hiroshi Onishi, Yoko Kayukawa